DelveInsight’s, “Metastatic Liver Cancer Pipeline Insight” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic-Liver-Cancer pipeline landscape. It covers the Metastatic Liver Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Metastatic Liver Cancer Pipeline Report to explore emerging therapies, key Metastatic Liver Cancer Companies, and future Metastatic Liver Cancer treatment landscapes @ Metastatic Liver Cancer Pipeline Outlook Report

Key Takeaways from the Metastatic Liver Cancer Pipeline Report

• In March 2025, Akeso announced a phase II Study to Evaluate the Efficacy and Safety of AK104 Plus Lenvatinib and TACE in the Treatment of Unresectable, Non-metastatic Hepatocellular Carcinoma.
• In March 2025, BeiGene conducted a study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) by central site imaging facility per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
• In February 2025:- Alethia Biotherapeutics:- This Phase II study will recruit 17 colorectal cancerpatients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver metastases resection surgery with or without primary cancer resection. One cycle of treatment will consist of 14 days (2 weeks).
• In February 2025:- Medivir:- This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.
• In February 2025:- Kamya Sankar:-This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases.
• In February 2025:- Tango Therapeutics Inc.:- This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
• In February 2025:- Bristol-Myers Squibb:- The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
• DelveInsight’s Metastatic Liver Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Liver Cancer treatment.
• The leading Metastatic Liver Cancer Companies such as Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
• Promising Metastatic Liver Cancer Therapies such as ThermoDox® (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG®-1, AV-299, RO7119929, Tocilizumab, and others.

Discover how the Metastatic Liver Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Metastatic Liver Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Liver Cancer Clinical Trials and Studies

Metastatic Liver Cancer Emerging Drugs Profile

• exoASO STAT6: Codiak BioSciences

exoASO™-STAT6 is an exosome therapeutic candidate engineered using our engEx™ Platform to overexpress Codiak’s novel protein scaffold, PTGFRN, to selectively target uptake in M2 polarized tumor-associated macrophages. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

• STP 705: Sirnaomics

STP705, is a dual TGF-ß1/COX-2 inhibitor. TGF-ß1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

• ONCR 177: Oncorus

ONCR-177, our lead product candidate, is an intratumorally administered Herpes Simplex Virus (HSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

The Metastatic Liver Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Liver Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Liver Cancer Treatment.
• Metastatic Liver Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Liver Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Liver Cancer market.

Get a detailed analysis of the latest innovations in the Metastatic Liver Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Metastatic Liver Cancer Unmet Needs

Metastatic Liver Cancer Companies

Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.

Metastatic-Liver-Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Metastatic Liver Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Liver Cancer Therapies and key Metastatic Liver Cancer Developments @ Metastatic Liver Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Liver Cancer Pipeline Report

• Coverage- Global
• Metastatic Liver Cancer Companies- Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
• Metastatic Liver Cancer Therapies- ThermoDox® (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG®-1, AV-299, RO7119929, Tocilizumab, and others.
• Metastatic Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Metastatic Liver Cancer drug development? Find out in DelveInsight’s exclusive Metastatic Liver Cancer Pipeline Report—access it now! @ Metastatic Liver Cancer Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic-Liver-Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic-Liver-Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name :Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name :Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ONCR 177: Oncorus
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name :Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic-Liver-Cancer Key Companies
21. Metastatic-Liver-Cancer Key Products
22. Metastatic-Liver-Cancer- Unmet Needs
23. Metastatic-Liver-Cancer- Market Drivers and Barriers
24. Metastatic-Liver-Cancer- Future Perspectives and Conclusion
25. Metastatic-Liver-Cancer Analyst Views
26. Metastatic-Liver-Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight